Mechanisms of Action of MicroRNAs in Infantile Hemangioma Tissue and Vascular Endothelial Cells in Different Periods

Junjiang Chen*
Chen Li*
Yuqiang Li
Yu Wang

* Co-first authors
Corresponding Author: Yu Wang, e-mail: cnyuwang@126.com
Source of support: This study was supported by the Natural Science Foundation of Liaoning Province Science and Technology Department (No. 2015020341), and the Liaoning Medical College President Fund, Clinical Medicine Construction Special Fund (No. XZJJ20140215)

Background: The aim of this study was to investigate the developmental mechanisms of infantile hemangioma (IH) from the microRNA level.

Material/Methods: A total of 63 biological specimens of IH were obtained from the First Affiliated Hospital of Jinzhou Medical University and we assessed related miRNAs. Magnetic bead sorting, endocytosis test, canalization assay, and immunofluorescence detection were performed. The IH-derived cells were transfected with related factors and then we assessed the apoptosis and invasion.

Results: The contents of MiR-455, miR-206, and miR-29a in the proliferative period group (PP) were lower than in the complete regression period group (CR) (P<0.05), and the content of miR-29a in the regression period group (RP) was lower than in the group CR (P<0.05). The post-sorting proliferation capacity was faster than in human umbilical vein endothelial cells, and IH-derived vascular endothelial cells (VECs) exhibited faster canalization ability. The cells transfected with miR-29a exhibited obvious apoptosis 48 h later, the cells transfected with miR-206 exhibited significantly reduced proliferation capacity as well as apoptosis 48 h later, and the invasion capacity was decreased 24 h after transfection.

Conclusions: miR-29a, miR-206, and miR-455 are differently expressed in different periods of IH, and may participate in regulating multiple functions during the progression of IH.

MeSH Keywords: Hemangioma • Infant • MicroRNAs

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/902374

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS] [Index Copernicus]
Background

IH is the most common soft tissue neoplasm in infants and young children. The morbidity in European populations as about 10% and is about 1% in Asian neonates, and its sex ratio is about 1: 3 (male to female) [1]. This disease usually occurs within 1–2 weeks after birth, which then rapidly enters the proliferative period and shows rapid tumor growth within a few weeks or months; most of the tumors spontaneously degrade without any treatment, and about 10% of the children have no significant skin residual change. However, it is generally believed that children with IH regressing after the age of 6 years old have greatly increased likelihood of having scars and other skin lesions. About 20% of IH cases need clinical treatment due to its significant growth or invasion, which thus affects normal physiological functions or even threatens the lives of infants and young children [2–5]. Because 80% of IH affects the head and neck, early intervention is important. Clinical treatments of IH vary, but they all have some level of risks and defects [6–8]. Because the pathogenesis and regression mechanism of IH are unknown, invalid cases also exist in various treatment methods, and there is a lack of effective risk assessment indicators for IH. Some over-treatment and blind treatment still occurs, so it is necessary to further study the mechanisms of the occurrence and development of IH to more effectively guide clinical treatment.

Recent studies have suggested that the regression of IH may be related to the roles of mesenchymal stem cells, as well as to cell transformation to some extent, but there is no final conclusion yet [9–14]. The specific pathogenesis of IH is unknown; therefore, further research is needed to explore the mechanisms and to determine during which periods the regulation of microRNA occurs, as an important regulator of post-transcriptional regulation in IH.

MicroRNA (miRNA) is a small RNA family member with about 20 nucleotides that can partially or completely recognize the specific target mRNA, completely degrade mRNA, or only inhibit the mRNA expression at the transcriptional level, thus completely silencing or inhibiting the formation of target protein(s). miR-424 can inhibit the expressions of MEK1 and Cyclin E1 through affecting their signaling pathways, and the low level of miR-424 in senile hemangioma is likely to contribute to the abnormal proliferation of endothelial cells through this signaling pathway [15]. In the present pre-experiment, our bioinformatics analysis showed that miR-206a, miR-29a, and miR-455 have important roles in IH expression. Whether the change in miRNAs activity plays a role in the course of IH is unclear. To test our hypothesis, we explored the expressions of miRNAs specifically related to the pathogenesis of IH. We also performed RT-PCR and confirmed that miRNAs were differently expressed in the proliferative period and regression period of IH. Furthermore, the endothelial cells of IH were further isolated and we transfected specific miRNAs to study the important roles of these miRNAs.

Material and Methods

Biological samples

The 63 IH biological samples were provided by the biological sample library, First Affiliated Hospital of Jinzhou Medical University, which were enrolled from January 2014 to August 2015. All the samples were confirmed by pathology, including 26 cases in the proliferative period, 21 cases in the regression period, and 16 cases in the complete regression period. All the samples were obtained with signed informed consent and approval from the Ethics Committee of the First Affiliated Hospital of Jinzhou Medical University.

RT-PCR

The cryopreserved tissue samples were removed and added into Trizol reagent (Invitrogen, USA, 100 mg of tissue/1 ml), followed by grinding in liquid nitrogen and extracting the total RNA by phenol-chloroform extraction. The total RNA was then analyzed using 1% agarose gel electrophoresis to evaluate its quality. The qualified RNA was then sequenced and quantitatively analyzed by TaKaRa to compare the expression levels of miR-206, miR-455, and miR-29a in the 2 different tissues. The design and synthesis of the primers for miR-206, miR-455, miR-29a, and U6 were performed by TaKaRa (Japan).

Magnetic bead sorting

The in vitro IH samples were rinsed twice in cold PBS (Sigma, USA) and then transferred into collagenase II (Sigma, USA)-containing EP tubes, followed by 40-min incubation at 37°C, digestion, filtration through a 200-mesh cell filter, and 3-min centrifugation (2000 rpm). After the supernatant was discarded, 60 μl of EGM-2 serum-free medium (PromoCell, USA) was added to resuspend the cells, then 20 μl of Immunoglobulin Fc receptor inhibitor was added and vortexed evenly, followed by adding 20 μl of CD31-conjugated magnetic beads for magnetic bead sorting after 30-min agitation. The eluent collected from the column was regarded as the CD31-positive cells (Hem EC).

Endocytosis test

The Hem EC was cultured in 6-well plates, and the culture medium in the 6-well plates was then removed. After washing 3 times with PBS, EGM-2MV/20% FBS culture medium-diluted 10 μg/ml Dil (Life Technologies, USA), labeled acetyl LDL was added (DIL-Ac-LDL) for 4-h incubation in 1 incubator. The
Dil-Ac-LDL solution was then removed for the fluorescence observation.

**VECs canalization assay**

We added 30 μl of pure Matrigel gel (BD, USA) into the wells of cold 96-well plates and incubated them at 37°C for 30 min for gel polymerization. The Hem EC was set as the experimental group, the fibroblasts were set as the negative control group, and the human umbilical venous endothelial cells (HUVECs) were set as the positive control group (CAS Cell Bank, China). All the cells were observed after incubation for 30 min, 1 h, 3 h, and 6 h at 37°C.

**Immunofluorescence**

The cell climbing slices of the groups were fixed with 4% paraformaldehyde for 10 min, followed by 10-min incubation with 0.25% TritonX-100/5% DMSO-PBS, PBS rinsing, 15-min 1.5% H₂O₂-PBS incubation at 37°C, and 30-min goat serum incubation. The primary antibodies rabbit anti-human Von Willebrand Factor (VWF, Santa Cruz, USA 1: 200) and mouse anti-human CD31 (1: 50) were then added together with PBS as the control for overnight incubation at 4°C. The secondary antibodies goat anti-rabbit IgG-Cy2 and goat anti-mouse IgG-FITC (1: 100) were then added for 30-min incubation at 37°C. Then, 1: 1000 DAPI was used to stain the cell nuclei, followed by oil-mounting, photographing, and observation.

**miRNAs transfection**

The tubes with the miRNA powders (analogs and inhibitor) were centrifuged at 2500 rpm for 1 min. We then added 125 μl of DEPC water into the 2.5 nm miRNA powder-containing centrifuge tube to form a 20-μM miRNA suspension. According to different culture plates, different amounts of miRNA together with the appropriate amount of RNAI-MAX transfection reagent were added into the serum-free opti-MEM medium (Gibco, USA), mixed evenly, and allowed to settle for 10-min. The miRNA mixture was then added to the RNAI-MAX mixture and then added to the culture system 30 min later. At 8 h after transfection, the control group was selected to observe whether the Fam-labeled miR-67 was transfected into the cells to determine whether the miR-67 transfection was successful.

**Cell proliferation assay**

The Hem EC single-cell suspension was seeded into 500 ng/ml fibronectin-coated 96-well plates (100 μl per well, 2×10⁵ cells). Three wells were set as 1 group, with a total of 8 groups (2 plates for the reproduction): the groups with the analogs and inhibitor of MiR-206, miR-29a, and miR-455, respectively, as well as 1 blank control group and 1 fluorescence-miR-67 control group. The cells were incubated for 24 h before transfection and were assessed at 24 h after transfection. We added 10 μl of cck-8 solution into each well and incubated them at 37°C for 4 h. The culture was then terminated, and the absorbance of each well was measured at 460 nm using a full-wavelength scanning multifunctional reading instrument, and the second plate was assessed 48 h later in the same manner.

**Apoptosis assay**

At 48 h after transfection, the cells were collected for apoptosis assay. Cells were digested using EDTA-free 0.25% trypsin, followed by rinsing twice with PBS, 30-min incubation with 300 μl of the loading buffer (apoptotic kit) and 2.5 μl of AV reagent in the dark at room temperature. Then, cells were mixed with the PI reagent and subjected to flow cytometry.

**Transwell cell invasion assay**

The primary Hem EC cells cultured in 6-well plates were used for miRNA transfection. Basal-coating membrane (50 mg/L Matrigel, 1: 4) was used to coat the upper chamber surface of the basal membrane of the cold Transwell chamber, which was then kept at 37°C for 30 min to make the Matrigel gel polymerize. After transfection, the cells were digested and re-suspended in 0.1% BSA-containing serum-free medium. The cell density was then adjusted to 2×10⁵/ml, and 200 μl of the cell suspension was added into the Transwell chamber together with 500 μl of 20% FBS-containing EGM-2MV medium added into the lower chamber of the 24-well plates (making sure no bubbles were generated between the lower culture medium and the chamber). The cells were then divided into 8 groups (the analogs and inhibitors of miR-206, miR-29a, and miR-455, respectively, the blank control group, and the fluorescence-miR-67 control group; each group contained 3 wells). After 12-h conventional culture, 4% formaldehyde was added to fix the cells for 30 min, followed by pure methanol fixation for 10 min, 40-min 0.1% crystal violet staining, and rinsing with water. Five visual fields were used for the cell counting.

**Statistical analysis**

The results were statistically analyzed using the SPSS19.0 for Windows software package. The measurement data were expressed as mean ± standard deviation (x±s). The t test was used to compare the data between the 2 groups, and single-factor analysis of variance was used for the comparison among multiple groups, with P<0.05 considered as a statistically significant difference.
Results

Expression of miR-206, miR-455, and miR-29a

The results revealed that miR-455, miR-206, and miR-29a in group PP were significantly lower than in group CR (internal reference U6, group CR as the control, P <0.05). The level of miR-29a in group RP was significantly lower than in group CR (P <0.05) (Figure 1).

Cells obtained

Microscopy revealed that the cells began to adhere to the wall about 4 h later and showed polygonal morphology. The cell division and proliferation were obvious 24 h later, and exhibited the morphological characteristics of Hem EC (Figure 2).

The comparison of the growth curves of IH CD31-positive cells and HUVECs is shown in Figure 3, which shows the IH CD31-positive cells had stronger proliferative capacity, and the difference was statistically significant (P<0.05).

HUVECs showed cell contact inhibition and stopped growth after they covered the bottom of the culture flask. The morphology of the cells was homogeneous; however, the Hem EC cells kept growing even after they covered the bottom of the culture flask. Cell morphology began to appear disorderly, and spindle cells began to increase due to intercellular compression (Figure 4).

Intracellular LDL uptake assay

After 4-h co-culturing with Dil-Ac-LDL, red punctiform fluorescence was observed in the cytoplasm of the IH CD31-positive cells, suggesting that the sorted cells had the role of phagocytizing LDL; therefore, they had the characteristics of VECs (Figure 5).

VECs canalization assay

The results showed that the CD31-positive cells had canalization ability in the Matrigel, which showed cell deformation migration and canalization earlier than in the HUVECs. At 24 h after incubation in Matrigel, the CD-31 cells gradually exhibited cell aggregation, but the fibroblasts did not show canalization in Matrigel (Figure 6).

Surface markers

A further experiment validated the purity of the cells, and determined that they could be used in the further cell experiment study. Early-generation cells were almost all positive cells, which gradually decreased with passaging, and the positive rate of the 6th generation cells was about 40% (Figure 8), suggesting that the IH CD31-positive cells were the Hem EC, and had certain purity in certain generations.

miRNA transfection

The Fam-labeled miR-67 was used as the positive control to count the cells 8 h after Fam-miR-67 transfection; 93±2% of the cells showed green fluorescence (Figure 9), indicating that the transfection conditions were good and that the cell transfection rate met the requirements for further studies.

Cell proliferation assay

Compared with the control group, the numbers of cells transfected with miR-206 analog and miR-455 mimetic were significantly decreased 48 h after transfection, and the differences were statistically significant (P<0.05). The numbers of cells transfected with miR-206 inhibitor and miR455 inhibitor were slightly higher, but the differences were not significant (P>0.05). The numbers of the cells transfected with miR-29a analog and the inhibitor showed no significant change (Figure 10). The results suggested that increasing miR-206 and miR-455 significantly inhibits the proliferation of Hem EC cells.

Apoptosis assay

The Hem EC cells were harvested 48 h after transfection with miRNAs analogs or inhibitors and were compared with the negative control group (with blank transfection reagent). The
results of flow cytometry showed that the apoptotic level of the cells transfected with the miR-206 analog and miR-29a analog was obvious (P<0.05), and the total apoptotic ratios were significantly different from the control group (P<0.05). The cells transfected with the miR-206 analog were mainly early apoptotic cells at 48 h after transfection (the apoptosis occurred late), but those transfected with miR-29a analog were mainly late apoptotic cells (the apoptosis occurred early), indicating that these 2 analogs had different pathways when triggering the apoptosis of Hem EC cells. There was no significant difference in the apoptotic ratio among other groups (Figure 11).

**Transwell cell invasion assay**

A series of Transwell invasion assays was performed to detect changes in Hem EC cells after transfection with course-related
miRNAs. The results showed that after 12-h chemotactic culture, the fibroblast group showed no cells in the lower Transwell chamber. Compared with the blank control group, the cells in the control group showed no significant difference (P>0.05), indicating that the transfection reagent had no significant effect on cell invasive ability. Compared with the control group, we found that the invasive ability was significantly decreased after the miR-206 analog was transfected, while the invasive ability was significantly increased after the miR-206 inhibitor was transfected (P<0.05). There was no significant between other transfection groups and the control group (P>0.05) (Figure 12).

**Discussion**

**Sorting and identification of IH endothelial cells**

In our study, we used dispase and collagenase to digest and prepare the single-cell suspension, followed by CD31-coated magnetic bead sorting to select the cells. The advantages of the culture are; the total number of cells can be increased significantly because large tissue masses have been digested; the cells can be obtained by short-term digestion, so the cycle is short; and the cells are sorted by magnetic beads, so the purity is high.

**Figure 4.** (A) HUVECs and (B) IH CD40-positive cells (×100).

**Figure 5.** Intracellular LDL uptake assay of CD31-positive cells (×100). (A) Normal cells under light microscope. (B) Red fluorescent cells excited by green laser in the same visual field.
The identification of IH-derived VECs can be comprehensively performed from cell morphology, phenotype, or biochemical and functional aspects.

**Cell morphology and growth performance**

Most VECs are polygonal, flat, thin, and translucent, with clear nuclei; when the cells proliferate, they will grow in a “paving stone”-like mosaic arrangement. The primary Hem EC cells have a typical polygonal structure, which shows a “paving stone”-like cell growth structure and are more closely arranged than the HUVECs, and their contact inhibition is relatively poor, which is probably related to their stronger proliferation ability. The cells exhibit spindle-shaped structure when they fill the bottom of the culture flask and squeeze together, but HUVECs retain their polygonal structure, so they exhibit the phenomenon of cell floating. Hem EC was also observed to have a stronger proliferative capacity than HUVECs in our study.

**LDL phagocytosis of VECs**

VECs can specifically phagocytose LDL, and we found that the Hem EC cells possessed the same ability as HUVECs in phagocytosing Dil-Ac-LDL.
Specific markers

VECs have a specific VII factor-associated antigen (also known as vWF), as well as a specific CD31 on their surface (also known as platelet endothelial cell adhesion molecule -1, PECAM-1), which are the specific markers of VECs. We used vWF and CD31 as the positive markers for the screening.

The cells exhibited a higher positive rate, but this decreased over time. We first suspected the possibility that the sorted cells were contaminated with fibroblasts, but after we eliminated the fibroblasts with differential attachment and trypsin digestion, this phenomenon still existed. We believe that this may be related to the differentiation of the Hem EC cells during the culture.
Figure 9. Fam-miR-67 transfection assay (×100). (A) Observation under one ordinary microscope. (B) Observation under a fluorescence microscope. (C) Specific fluorescence-displaying site.

Figure 10. Changes in cell proliferation of Hem EC cells after being transfected with related miRNAs or inhibitors. * P<0.05 vs. control.

Figure 11. Changes in apoptotic levels in Hem EC after being transfected with miR-206 analog and miR-29a analog. * P<0.05 vs. control.

Figure 12. Changes in invasive ability of Hem EC cells after being transfected with miRNAs analogs or inhibitors. * P<0.05 vs. control.

Canalization assay

VECS have the characteristics of canalization in their basement membrane-like structure. In our study, the Matrigel gel was used as the medium, in which the cells can achieve cell-cell junction and form a lumen-like structure by secreting matrix metalloproteinase and mutual chemotaxis, but other cells, such as fibroblasts, do not have this function. HUVECs can also form a regular lumen-like blood vessel cross-sectional structure in matrix glue, and we found that Hem ECs had stronger activity and earlier canalization phenomenon; however, the canals formed by Hem EC were less regular than with HUVECs, showing different-size lumens, obvious cell aggregation, and quick regression of the canals (showing further migration and aggregation of the cells, lumen disappearance, and cell cluster formation). This may be caused by the significant proliferation of the cells that increased the cell density, further shortened the distance among the cells, and finally formed the tumor-like structure. However, HUVECs exhibited stable and sustainable canalization ability lasting several days. In addition, it has been reported that, except for Hem EC, Hem SC also has good canalization characteristics, together with a stronger intercellular junction morphology [16–20], but IH-derived pericytes probably have no significant canalization ability [21,22].
Roles of microRNA in IH

Studies of tumor diseases have revealed that miRNAs are closely related to the occurrence and development, metastasis, and cell transformation of tumors [23]. miR-424 has been found to be able to inhibit the expressions of MEK1 and Cyclin E1 through acting on their signaling pathways. Low levels of miR-424 in senile hemangiomas are likely to promote the abnormal proliferation of VECs through this signaling pathway [15,24]. Through our studies using RT-PCR, we have found that miR-206, miR-29a, and miR-455 are differentially expressed in different biological samples, which may play important roles in the development of IH.

We found that the changes of miR-206 have significant effects on the Hem EC cells through the cell proliferation assay, apoptosis assay, and invasion assay, and that increasing the intracellular miR-206 level can significantly reduce the proliferative ability of Hem EC, increase the apoptosis, and decrease the invasive ability, which may play an important regulatory role in inhibiting the proliferation of IH cells, promoting the regression, and reducing the tumor expansion toward surroundings. Our results showed that increasing the miR-29a level in Hem EC can significantly increase apoptosis but have no significant effect on proliferation and cell invasion, indicating that miR-29a may play an important role in the regression process of IH. Increasing the miR-455 level in Hem EC could inhibit proliferation while having no significant effect on apoptosis and cell invasion, suggesting that miR-455 may play an important regulatory role in the development and proliferation of IH. Therefore, miR-206, miR-29a, and miR-455 may play certain roles in promoting the progression of IH, but the specific mechanisms need further study.

Conclusions

MiR-29a, miR-206, and miR-455 are differentially expressed in the miRNAs expression spectrum at different IH stages. These differentially expressed miRNAs may be involved in regulating various IH-related functions. miR-29a may affect the disease course through altering the apoptosis of IH vascular endothelial cells, especially its post-transcriptional regulation of the spontaneous regression of IH. miR-206 may affect the disease course and play an important post-transcriptional regulatory role in the spontaneous regression of IH by altering the proliferation, apoptosis, and invasiveness of IH vascular endothelial cells.

Conflicts of interest

The authors declare no conflict of interest.

References:

1. Jia L, Huang X, Zhang Wf, Zhao YF: Human monocyte-derived hemangioma-like endothelial cells: Evidence from an in vitro study. Cardiovasc Pathol, 2008; 17: 212–18
2. Bertoni N, Pereira LM, Severino FE et al: Integrative meta-analysis identifies microRNA-regulated networks in infantile hemangioma. BMC Med Genet, 2016; 17: 4
3. Mehrian-Shai R, Yalon M, Moshe I et al: Identification of genomic aberrations in hemangioblastoma by droplet digital PCR and SNP microarray highlights novel candidate genes and pathways for pathogenesis. BMC Genomics, 2016; 17: 56
4. Zha JY, Zhang W, Ren JG et al: Characterization of endothelial microparticles induced by different therapeutic drugs for infantile hemangioma. J Cardiovasc Pharmacol, 2015; 66: 261–69
5. Haggstrom AN, Drolet BA, Baselga E et al: Prospective study of infantile hemangiomas: Clinical characteristics predicting complications and treatment. Pediatrics, 2006; 118: 882–87
6. Il Y, Li X, Xiao X et al: Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells. J Pediatr Surg, 2012; 47: 2216–23
7. Kleinman ME, Greives MR, Churgin SS et al: Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arterioscler Thromb Vasc Biol, 2007; 27: 2664–70
8. Greenberger S, Boscolo E, Adini I et al: Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. N Engl J Med, 2010; 362: 1005–13
9. Yu Y, Flint AF, Mulliken JB et al: Endothelial progenitor cells in infantile hemangioma. Blood, 2004; 103: 1373–75
10. Mai HM, Zheng JW, Wang YA et al: CD133 selected stem cells from proliferating infantile hemangioma and establishment of an in vivo mice model of hemangioma. Chin Med J (Engl), 2013; 126: 88–94
11. Pittman KM, Losken HW, Kleinman ME et al: No evidence for maternal-fetal microchimerism in infantile hemangioma: A molecular genetic investigation. J Invest Dermatol, 2006; 126: 2533–38
12. Xu D, O TM, Shartava A et al: Isolation, characterization, and in vitro propagation of infantile hemangioma stem cells and an in vivo mouse model. J Hematol Oncol, 2011; 4: 54
13. Khan ZA, Melero-Martin JM, Wu X et al: Endothelial progenitor cells from infantile hemangioma and umbilical cord blood display unique cellular responses to endostatin. Blood, 2006; 108: 915–21
14. Boscolo E, Mulliken JB, Bischoff J: VEGF-R1 mediates endothelial differentiation and formation of blood vessels in a murine model of infantile hemangioma. Am J Pathol, 2011; 179: 2266–77
15. Nakashima T, Jinnin M, Etoh T et al: Down-regulation of miR-424 contributes to the abnormal angiogenesis via MEK1 and cyclin E1 in senile hemangioma: its implications to therapy. PLoS One, 2010; 5: e14334
16. Barnés CM, Huang S, Kaipainen A et al: Evidence by molecular profiling for a placental origin of infantile hemangioma. Proc Natl Acad Sci USA, 2005; 102: 19097–102
17. Przewirot P, Sikiewicz A, Wyka K, Andrzejewska E: Serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in children with hemangiomas and vascular malformations – preliminary report. Pediatr Dermatol, 2009; 26: 399–404
18. Zhang L, Lin X, Wang W et al: Circulating level of vascular endothelial growth factor in patients with infantile hemangioma. J Plast Reconstr Aesthet Surg, 2010; 63: 1913–20
19. Ritter MR, Reinish J, Friedlander SF, Friedlander M: Myeloid cells in infantile hemangioma and establishment of an in vivo mouse model. J Pediatr Surg, 2005; 40: 1159–65
20. Arai Y, Sugimachi S, Hara Y et al: Angiogenic factor expression is associated with the occurrence and clinical course of infantile hemangioma. Int J Oncol, 2009; 34: 333–36
21. Chen J. et al.: MicroRNAs and infantile hemangioma. © Med Sci Monit, 2017; 23: 4214-4224

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
21. Khan ZA, Boscolo E, Picard A et al: Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J Clin Invest, 2008; 118: 2592–99

22. Boscolo E, Mulliken JB, Bischoff J: Pericytes from infantile hemangioma display proangiogenic properties and dysregulated angiopoietin-1. Arterioscler Thromb Vasc Biol, 2013; 33: 501–9

23. Giovannetti E, van der Veide A, Funel N et al: High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. PLoS One, 2012; 7: e49145

24. Strub GM, Kirsh AL, Whipple ME et al: Endothelial and circulating C19MC microRNAs are biomarkers of infantile hemangioma. JCI Insight, 2016: 1: e88856